EZH2 and breast cancer: Among the highly recurrent oncogenes amplified with overexpression in specific tumors, including MYC in colorectal cancer, MYCN in colorectal and liver cancers, and HIST1H3B and EZH2 in colorectal, lung, liver, and breast cancers, there was no significance between their status of amplification with overexpression and cancer stage (Supplementary Table 3) when significance was defined as P < 0.05 (Fisher’s exact test).